Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine
- PMID: 20187746
- PMCID: PMC2922992
- DOI: 10.1086/651147
Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine
Abstract
To date, no vaccine is available to prevent human schistosomiasis. We have targeted a protein of Schistosoma mansoni that plays an important role in the surface membrane renewal process, a mechanism widely believed to be utilized by the parasite as an immune evasion strategy. Sm-p80 antigen is a promising vaccine target because of its documented immunogenicity, protective efficacy, and antifecundity effects observed in both experimental murine and nonhuman primate models of this infectious disease. In the present study, we report that, in a vector approved for human use (VR1020), an Sm-p80-based DNA vaccine formulation confers a 46% reduction in the worm burden in a baboon (Papio anubis) model. Baboons vaccinated with Sm-p80-VR1020 had a 28% decrease in egg production after challenge with the infectious parasite. Sm-p80-VR1020 vaccine elicited robust immune responses to specific antigen Sm-p80, including immunoglobulin (Ig) G, its subtypes IgG1 and IgG2, and IgA and IgM in vaccinated animals. When stimulated in vitro with recombinant Sm-p80, peripheral blood mononuclear cells and splenocytes from baboons vaccinated with Sm-p80-VR1020 produced considerably higher levels of T helper 1 response-enhancing cytokines (interleukin [IL]-2 and interferon-gamma) than T helper 2 (Th2) response-enhancing cytokines (IL-4 and IL-10). Peripheral blood mononuclear cells produced a significantly higher number of spot-forming units for interferon-gamma than for IL-4 in enzyme-linked immunosorbent spot assays. A mixed T helper 1/T helper 2 type of humoral and T cell responses was generated after immunization with Sm-p80-VR1020. These findings again highlight the potential of Sm-p80 as a promising vaccine candidate for schistosomiasis.
Conflict of interest statement
Authors do not have any commercial or other associations that might pose a conflict of interest.
Figures








Similar articles
-
Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.Vaccine. 2009 May 11;27(21):2830-7. doi: 10.1016/j.vaccine.2009.02.096. Epub 2009 Mar 10. Vaccine. 2009. PMID: 19366570 Free PMC article.
-
Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse.Parasite Immunol. 2010 Apr;32(4):252-8. doi: 10.1111/j.1365-3024.2009.01181.x. Parasite Immunol. 2010. PMID: 20398225
-
Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni.Parasite Immunol. 2009 Mar;31(3):156-61. doi: 10.1111/j.1365-3024.2008.01091.x. Parasite Immunol. 2009. PMID: 19222788 Free PMC article.
-
Human schistosomiasis mansoni: immune responses during acute and chronic phases of the infection.Acta Trop. 2008 Nov-Dec;108(2-3):109-17. doi: 10.1016/j.actatropica.2008.05.027. Epub 2008 Jun 5. Acta Trop. 2008. PMID: 18577364 Review.
-
Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.PLoS Negl Trop Dis. 2025 Jun 2;19(6):e0012956. doi: 10.1371/journal.pntd.0012956. eCollection 2025 Jun. PLoS Negl Trop Dis. 2025. PMID: 40455825 Free PMC article.
Cited by
-
Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.Parasitol Res. 2017 Nov;116(11):3175-3188. doi: 10.1007/s00436-017-5634-4. Epub 2017 Oct 12. Parasitol Res. 2017. PMID: 29026995 Free PMC article.
-
A comprehensive and critical overview of schistosomiasis vaccine candidates.J Parasit Dis. 2021 Jun;45(2):557-580. doi: 10.1007/s12639-021-01387-w. Epub 2021 Apr 25. J Parasit Dis. 2021. PMID: 33935395 Free PMC article. Review.
-
Schistosomiasis vaccines: where do we stand?Parasit Vectors. 2016 Sep 30;9(1):528. doi: 10.1186/s13071-016-1799-4. Parasit Vectors. 2016. PMID: 27716365 Free PMC article. Review.
-
Recent Advances and Methodological Considerations on Vaccine Candidates for Human Schistosomiasis.Front Trop Dis. 2021 Aug;2:719369. doi: 10.3389/fitd.2021.719369. Epub 2021 Aug 26. Front Trop Dis. 2021. PMID: 39280170 Free PMC article.
-
Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum).Acta Trop. 2011 May;118(2):142-51. doi: 10.1016/j.actatropica.2011.01.010. Epub 2011 Feb 18. Acta Trop. 2011. PMID: 21334302 Free PMC article.
References
-
- van der Werf MJ, de Vlas SJ, Brooker S, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003;86(2–3):125–39. - PubMed
-
- Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N Engl J Med. 2007;357(10):1018–27. - PubMed
-
- Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–25. - PubMed
-
- Doenhoff MJ, Hagan P, Cioli D, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology. 2009:1–11. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous